USPTO to issue reexamination certificate for Neuralstem's patent for neural stem cell technology


Neuralstem, Inc. (NYSE Amex: CUR) announced that it received notification that the United States Patent and Trademark Office (USPTO) has upheld the patentability, without amendment, of all claims in U.S. Patent No. 5,753,506 and intends to issue a reexamination certificate in due course.  This patent describes methods of culturing and expanding neural stem cells.  A reexamination request had been filed by a third-party requestor in September of 2009.

"We are of course pleased that the USPTO has upheld the patentability of all of our claims, without amendment.  U.S. Patent No. 5,753,506 is a core technology patent for Neuralstem," said Richard Garr, Neuralstem's President & CEO.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Liver cell aging can trigger multi-organ failure